...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: from IR/Chris
Reply New Message
Prev Message Back To Forum Threaded View Next Message

Hi xxx,

 

"This refers to a 6% royalty on net sales of ZEN-3694 to be paid by Zenith Epigenetics to Zenith Capital Corp, and that royalty stream is intended to be retained by Zenith Capital Corp in the event of the sale of Zenith Epigenetics.

 

Best regards,

 

Chris"

3 Recommendations
Reply New Message
Prev Message Back To Forum Threaded View Next Message
Share
Share
New Message
Please login to post a reply